Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 3/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 2/20 | 0.31 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20370982 | 0.93 | GLP1R (0.42) | GLP1RPOLBALDH1A1MAPT | |
| SCHEMBL20370980 | 0.93 | GLP1R (0.42) | GLP1RPOLBALDH1A1MAPT | |
| SCHEMBL20800976 | 0.92 | GLP1R (0.41) | GLP1RPOLBALDH1A1MAPT | |
| SCHEMBL22566689 | 0.86 | GLP1R (0.41) | GLP1RPOLBALDH1A1MAPT | |
| SCHEMBL24479396 | 0.85 | GLP1R (0.42) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL21287423 | 0.85 | GLP1R (0.42) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL20375331 | 0.85 | GLP1R (0.42) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL23870009 | 0.83 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL24264573 | 0.83 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL18708286 | 0.83 | GLP1R (0.43) | GLP1RPOLBLPAR3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257749-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257749-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFB, CFH, RNASE1 | GLP1R 4438/4885POLB 67/4885PLG 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.